Akèy › Ipètansyon atè pulmonè
Etid klinik pou Ipètansyon atè pulmonè ap rekrite nan Etazini
33 etid pou Ipètansyon atè pulmonè ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Aurora, CO7 etid
- Cincinnati, OH7 etid
- Boston, MA7 etid
- Kansas City, KS7 etid
- Durham, NC7 etid
- Nashville, TN7 etid
- Mountain View, CA7 etid
- Philadelphia, PA6 etid
- Seattle, WA5 etid
- New York City, NY5 etid
- Washington, DC4 etid
- Houston, TX4 etid
- Los Angeles, CA4 etid
- Dallas, TX4 etid
- Pittsburgh, PA4 etid
- Louisville, KY4 etid
- Minneapolis, MN3 etid
- Omaha, NE3 etid
- Jacksonville, FL3 etid
- Santa Barbara, CA3 etid
- Rochester, NY3 etid
- Salt Lake City, UT3 etid
- Atlanta, GA3 etid
- Scottsdale, AZ3 etid
- Richmond, VA3 etid
- Baltimore, MD3 etid
- San Francisco, CA3 etid
- Sacramento, CA3 etid
- St. Louis, MO3 etid
Pa eta
- Arizona6 etid
- Colorado7 etid
- Florid6 etid
- Georgia4 etid
- Kalifòni12 etid
- Kansas7 etid
- Kentucky4 etid
- Maryland5 etid
- Massachusetts7 etid
- Michigan3 etid
- Minnesota3 etid
- Missouri3 etid
- Nebraska3 etid
- New York6 etid
- North Carolina7 etid
- Ohio10 etid
- Oregon3 etid
- Pennsylvania8 etid
- South Carolina4 etid
- Tennessee8 etid
- Texas7 etid
- Utah3 etid
- Virginia3 etid
- Washington5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT07759804Spironolactone for Pulmonary Arterial Hypertension
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT01712620A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07218029Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07318597Hormonal, Metabolic, and Signaling Interactions in PAH
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Jiska laj 90 · Tout sèks · Mizajou Sep 25, 2026 · NCT01884051Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 23, 2026 · NCT07613099A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 16, 2026 · NCT07481981A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07143448An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT07365332Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 20 · Tout sèks · Mizajou Aug 21, 2026 · NCT04278404The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05464095Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT06992440A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Aug 10, 2026 · NCT07175038Xenon MRI Pulm Hypertension
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Aug 10, 2026 · NCT04991454A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 31, 2026 · NCT06481852Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 29, 2026 · NCT06274801A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Ap rekriteFaz 1/2Volontè an sante akeyi
Laj 18 a 100 · Tout sèks · Mizajou Jul 21, 2026 · NCT06649110A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 45 · Fanm · Mizajou May 26, 2026 · NCT07312227Repurposing Valsartan May Protect Against Pulmonary Hypertension
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou May 4, 2026 · NCT06053580A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
Ap rekriteFaz 1
Laj 18 a 60 · Tout sèks · Mizajou Apr 23, 2026 · NCT06872112Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
Ap rekriteFaz 2
Laj 1 a 17 · Tout sèks · Mizajou Apr 20, 2026 · NCT05587712Mobile Health Intervention to Improve Exercise in Pediatric PH
Ap rekrite
Laj 10 a 21 · Tout sèks · Mizajou Mar 27, 2026 · NCT06549452Pulmonary Hypertension SOLAR
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 24, 2026 · NCT04778046129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Feb 24, 2026 · NCT06104228129 Xenon Imaging in Patients Treated With Sotatercept
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Feb 24, 2026 · NCT06351345Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.